The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Update on NSAIDs Related Peptic Ulcers

비스테로이드소염제 관련 소화성 궤양의 최신지견

  • Choi, Dong Wook (Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Park, Sung Chul (Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Chun, Hoon Jai (Department of Internal Medicine, Korea University College of Medicine)
  • 최동욱 (강원대학교 의학전문대학원 내과학교실) ;
  • 박성철 (강원대학교 의학전문대학원 내과학교실) ;
  • 전훈재 (고려대학교 의과대학 내과학교실)
  • Published : 2014.06.01
⟨ Previous Next ⟩

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) have analgesic, antipyretic, and anti-inflammatory properties and are widely used for treating musculoskeletal and cardiovascular diseases. Notwithstanding these therapeutic efficacies, gastrointestinal toxicity is the major health problem associated with NSAID use. NSAID-related peptic ulcers are a well-known complication due to direct mucosal injury and cyclooxygenase inhibition. Risk factors for NSAID-related peptic ulcers include a prior history of peptic ulcer; age > 65 years; high-dose NSAID therapy; and concurrent use of aspirin (including low dose), corticosteroids, or anticoagulants. In addition, Helicobacter pylori infection is an independent risk factor; therefore, eradication therapy is recommended in high-risk patients using NSAIDs. Currently, misoprostol, H2-receptor antagonists, proton pump inhibitors, and COX-2 selective inhibitors are used to prevent and treat NSAID-related peptic ulcers. Further, strategic approaches are required through appropriate NSAID use and risk factor stratification to prevent NSAID-related peptic ulcers and associated complications.

Keywords

References

  1. Musumba C, Pritchard DM, Pirmohamed M. Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers. Aliment Pharmacol Ther 2009;30:517-531. https://doi.org/10.1111/j.1365-2036.2009.04086.x
  2. Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Antiinflamm Antiallergy Agents Med Chem 2012;11:52-64. https://doi.org/10.2174/187152312803476255
  3. Sinha M, Gautam L, Shukla PK, Kaur P, Sharma S, Singh TP. Current perspectives in NSAID-induced gastropathy. Mediators Inflamm 2013;2013:258209.
  4. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. World J Gastroenterol 2012;18:2147-2160. https://doi.org/10.3748/wjg.v18.i18.2147
  5. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010;24:121-132.
  6. Kim JJ, Kim N, Park HK, et al. Clinical characteristics of patients diagnosed as peptic ulcer disease in the third referral center in 2007. Korean J Gastroenterol 2012;59:338-346. https://doi.org/10.4166/kjg.2012.59.5.338
  7. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007;12:333-340. https://doi.org/10.1111/j.1523-5378.2007.00504.x
  8. Kim JI, Kim SG, Kim N, et al. Changing prevalence of upper gastrointestinal disease in 28 893 Koreans from 1995 to 2005. Eur J Gastroenterol Hepatol 2009;21:787-793. https://doi.org/10.1097/MEG.0b013e32830e285a
  9. Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 2013;15(Suppl 3):S3.
  10. Lee JH, Lee YC, Jeon SW, et al. Guidelines of prevention and treatment for NSAID-related peptic ulcers. Korean J Gastroenterol 2009;54:309-317. https://doi.org/10.4166/kjg.2009.54.5.309
  11. Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 2002;32(3 Suppl 1):25-32. https://doi.org/10.1053/sarh.2002.37217
  12. Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-738. https://doi.org/10.1038/ajg.2009.115
  13. Rostom A, Moayyedi P, Hunt R; Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009;29:481-496. https://doi.org/10.1111/j.1365-2036.2008.03905.x
  14. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-2099. https://doi.org/10.1001/archinte.160.14.2093
  15. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999;56:18-24.
  16. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin nonsteroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-1738. https://doi.org/10.1136/gut.2005.080754
  17. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-796. https://doi.org/10.7326/0003-4819-115-10-787
  18. Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004;63:759-766. https://doi.org/10.1136/ard.2003.015925
  19. Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570-576. https://doi.org/10.1097/00001648-200109000-00018
  20. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pepticulcer disease: a meta-analysis. Lancet 2002;359:14-22. https://doi.org/10.1016/S0140-6736(02)07273-2
  21. Cheung DY, Jung HY, Song HJ, et al. Guidelines of treatment for non-bleeding peptic ulcer disease. Korean J Gastroenterol 2009;54:285-297. https://doi.org/10.4166/kjg.2009.54.5.285
  22. Jaszewski R, Graham DY, Stromatt SC. Treatment of nonsteroidal antiinflammatory drug-induced gastric ulcers with misoprostol: a double-blind multicenter study. Dig Dis Sci 1992;37:1820-1824. https://doi.org/10.1007/BF01308074
  23. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-734. https://doi.org/10.1056/NEJM199803123381105
  24. Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther 2013;15(Suppl 3):S5. https://doi.org/10.1186/ar4177
  25. McDonagh MS, Carson S, Thakurta S. Drug Class Review: Proton Pump Inhibitors: Final Report Update 5. Portland: Oregon Health & Science University, 2009.
  26. Wu CY, Wu MS, Chen CJ, Li MC, Lin JT, Chen GH. The interaction of Helicobacter pylori infection and NSAIDs in cyclooxygenase-2 mRNA expression in gastric antral, corpus mucosa, and gastric ulcer. J Clin Gastroenterol 2005;39:50-55.
  27. Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study: NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000;160:1455-1461. https://doi.org/10.1001/archinte.160.10.1455
  28. Targownik LE, Metge CJ, Leung S, Chateau DG. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008;134:937-944. https://doi.org/10.1053/j.gastro.2008.01.010
  29. Lanza FL, Fakouhi D, Rubin A, et al. A double-blind placebo-controlled comparison of the efficacy and safety of 50, 100, and 200 micrograms of misoprostol QID in the prevention of ibuprofen-induced gastric and duodenal mucosal lesions and symptoms. Am J Gastroenterol 1989;84:633-636.
  30. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;(4):CD002296.
  31. Yeomans ND. New data on healing of nonsteroidal antiinflammatory drug-associated ulcers and erosions: Omeprazole NSAID Steering Committee. Am J Med 1998;104(3A):56S-61S. https://doi.org/10.1016/S0002-9343(97)00213-1
  32. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-1027. https://doi.org/10.1111/j.1572-0241.2001.03740.x
  33. Goldstein JL, Kivitz AJ, Verburg KM, Recker DP, Palmer RC, Kent JD. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol Ther 2003;18:125-132. https://doi.org/10.1046/j.1365-2036.2003.01650.x
  34. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004;127:1038-1043. https://doi.org/10.1053/j.gastro.2004.07.010
  35. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007;369:1621-1626. https://doi.org/10.1016/S0140-6736(07)60749-1
  36. Gargallo CJ, Lanas A. Is NSAIDs-related gastrointestinal damage preventable? J Dig Dis 2013;14:55-61. https://doi.org/10.1111/1751-2980.12019
  37. Lim YJ, Dial EJ, Lichtenberger LM. Advent of novel phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs with improved gastrointestinal safety. Gut Liver 2013;7:7-15. https://doi.org/10.5009/gnl.2013.7.1.7
  38. De Leest HT, Steen KS, Lems WF, et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter 2007;12:477-485. https://doi.org/10.1111/j.1523-5378.2007.00543.x
  39. Lai KC, Lau CS, Ip WY, et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003;17:799-805. https://doi.org/10.1046/j.1365-2036.2003.01528.x
  40. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Korean J Gastroenterol 2013;62:3-26. https://doi.org/10.4166/kjg.2013.62.1.3

Cited by

  1. 가슴쓰림 환자 30례에 대한 소건중탕 과립제의 임상적 고찰 vol.40, pp.6, 2019, https://doi.org/10.22246/jikm.2019.40.6.1193
  2. Underutilization of gastrointestinal prophylaxis in high-risk chronic nonsteroidal anti-inflammatory drug users in Korea vol.43, pp.3, 2014, https://doi.org/10.1007/s11096-020-01176-0